Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343516 | 0.80 | BRD4 (0.38) | BRD4 | |
| SCHEMBL25438335 | 0.80 | BRD4 (0.36) | BRD4 | |
| SCHEMBL25344946 | 0.77 | — | — | |
| SCHEMBL2070598 | 0.75 | PARP1 (0.56) | PARP1PDE3BPDE3ABRD4BRPF1 | |
| SCHEMBL20983200 | 0.75 | PARP1 (0.56) | PARP1PDE3BPDE3ABRD4BRPF1 | |
| SCHEMBL18128068 | 0.69 | PARP1 (0.44) | PARP1PDE3BPDE3A | |
| SCHEMBL21722859 | 0.69 | PARP1 (0.60) | PARP1PDE3BPDE3ABRD4CREBBP | |
| SCHEMBL25343286 | 0.69 | PDE3B (0.35) | PDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL25342592 | 0.69 | HTR2A (0.30) | — | |
| SCHEMBL20517076 | 0.67 | PDE3B (0.39) | PARP1PDE3BPDE3ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136577-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472734-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| CN-119095837-A | Heterocyclic derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136577-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | MALT1, SQSTM1, FKBP1A | PARP1 2244/4885PDE3B 4046/4885PDE3A 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.